A Cluster-Randomized Trial of a Centralized Clinical Pharmacy Cardiovascular Risk Service to Improve Guideline Adherence

Background Numerous studies have demonstrated the value of including pharmacists in team‐based care to improve adherence to cardiovascular (CV) guidelines, medication adherence, and risk factor control. However, there is limited information on whether these models can be successfully implemented mor...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacotherapy 2015-07, Vol.35 (7), p.653-662
Main Authors: Carter, Barry L., Coffey, Christopher S., Chrischilles, Elizabeth A., Ardery, Gail, Ecklund, Dixie, Gryzlak, Brian, Vander Weg, Mark W., James, Paul A., Christensen, Alan J., Parker, Christopher P., Gums, Tyler, Finkelstein, Rachel J., Uribe, Liz, Polgreen, Linnea A.
Format: Article
Language:English
Subjects:
Ambulatory Care
cardiovascular disease
Cardiovascular Diseases - prevention & control
clinical trial
diabetes
Guideline Adherence
Humans
Patient Compliance
Pharmaceutical Services
pharmacist management
Prospective Studies
Secondary Prevention
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Numerous studies have demonstrated the value of including pharmacists in team‐based care to improve adherence to cardiovascular (CV) guidelines, medication adherence, and risk factor control. However, there is limited information on whether these models can be successfully implemented more widely in diverse settings and populations. The purpose of this study is to evaluate whether a centralized, web‐based cardiovascular risk service (CVRS) managed by clinical pharmacists will improve guideline adherence in multiple primary care medical offices with diverse geographic and patient characteristics. Methods This study is a prospective trial in 20 primary care offices stratified by the percent of under‐represented minorities and then randomized to either the CVRS intervention or usual care. The intervention will last for 12 months and all subjects will have research visits at baseline and 12 months. The primary outcome is the difference in guideline adherence between groups. Data will also be ed from the medical record at 24 months to determine if the intervention effect is sustained after it is discontinued. Conclusions Patient enrollment will continue through 2016, with results expected in 2019. This study will provide information on whether a distant, centralized CVRS can be implemented in large numbers of medical offices, if it is effective in diverse populations, and if there is a long‐term sustained effect.
ISSN:0277-0008
1875-9114
DOI:10.1002/phar.1603